Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients: Therapeutic Drug Monitoring Uncovers the Impact on Drug Metabolism

被引:17
作者
Augustin, Marc [1 ,2 ]
Schoretsanitis, Georgios [1 ,2 ,3 ]
Hiemke, Christoph [4 ,5 ]
Gruender, Gerhard [6 ]
Haen, Ekkehard [7 ,8 ]
Paulzen, Michael [1 ,2 ,9 ]
机构
[1] Rhein Westfal TH Aachen, Fac Med, Dept Psychiat Psychotherapy & Psychosomat, Aachen, Germany
[2] JARA Translat Brain Med, Aachen, Germany
[3] Univ Hosp Psychiat, Bern, Switzerland
[4] Univ Med Ctr Mainz, Dept Psychiat & Psychotherapy, Mainz, Germany
[5] Univ Med Ctr Mainz, Inst Clin Chem & Lab Med, Mainz, Germany
[6] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Dept Mol Neuroimaging, Mannheim, Germany
[7] Univ Regensburg, Dept Psychiat & Psychotherapy, Clin Pharmacol, Regensburg, Germany
[8] Univ Regensburg, Dept Pharmacol & Toxicol, Regensburg, Germany
[9] Alexianer Hosp, Aachen, Germany
关键词
RISPERIDONE; PHARMACOKINETICS; FLUVOXAMINE; GENOTYPE;
D O I
10.4088/JCP.17m12086
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: For certain psychotropic drugs, such as clozapine or olanzapine, the influence of smoking on drug metabolism is well studied. Tobacco smoke increases the metabolism of drugs that are substrates for cytochrome P450 (CYP) 1A2 due to CYP induction. The antidepressant duloxetine, acting as a serotonin-norepinephrine reuptake inhibitor, is mainly metabolized via CYP1A2. To date, little is known about the influence of smoking on serum duloxetine concentrations. Methods: A therapeutic drug monitoring database consisting of plasma concentrations of duloxetine collected from January 2013 to June 2017 was analyzed. A group of nonsmoking patients undergoing treatment with duloxetine (n = 89) was compared to a group of active smokers also receiving duloxetine (n = 36). Serum concentrations of duloxetine and dose-adjusted serum concentrations were compared using non-parametric tests. Results: Groups did not differ concerning sex (P = .063), but the group of active smokers was younger (P < .001) and received higher daily doses of duloxetine (P = .001). Smokers showed significantly lower median serum duloxetine concentrations (38.4% lower, P = .002) and 53.6% lower dose-adjusted serum concentrations (0.325 [ng/mL]/[mg/d] in smokers vs 0.7 [ng/mL]/[mg/d] in nonsmokers, P < .001). Conclusions: Despite higher daily doses, smokers had considerably lower serum duloxetine concentrations. The induction of CYP1A2 by tobacco smoke is a clinically relevant factor for drugs that are substrates for CYP1A2. Clinicians should actively assess smoking status, inform patients about the effect of smoking on duloxetine metabolism, and anticipate higher serum concentrations in the case of smoking cessation. Therapeutic drug monitoring ensures treatment efficacy by enabling the personalizing of treatment, as smokers need higher duloxetine doses to target serum concentrations within the therapeutic reference range.
引用
收藏
页数:5
相关论文
共 27 条
  • [1] [Anonymous], 2010, DUL PRESCR INF
  • [2] Cigarette smoking and major depression
    Covey, LS
    Glassman, AH
    Stetner, F
    [J]. JOURNAL OF ADDICTIVE DISEASES, 1998, 17 (01) : 35 - 46
  • [3] Time response of cytochrome P450 1A2 activity on cessation of heavy smoking
    Faber, MS
    Fuhr, U
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) : 178 - 184
  • [4] The influence of smoking on the serum level of duloxetine
    Fric, M.
    Pfuhimann, B.
    Laux, G.
    Riederer, P.
    Distler, G.
    Artmann, S.
    Wohischlaegier, M.
    Liebmann, M.
    Deckert, J.
    [J]. PHARMACOPSYCHIATRY, 2008, 41 (04) : 151 - 155
  • [5] Nicotine dependence and psychiatric disorders in the United States - Results from the National Epidemiologic Survey on Alcohol and Related Conditions
    Grant, BF
    Hasin, DS
    Chou, SP
    Stinson, FS
    Dawson, DA
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2004, 61 (11) : 1107 - 1115
  • [6] Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
    Hiemke, C.
    Bergemann, N.
    Clement, H. W.
    Conca, A.
    Deckert, J.
    Domschke, K.
    Eckermann, G.
    Egberts, K.
    Gerlach, M.
    Greiner, C.
    Gruender, G.
    Haen, E.
    Havemann-Reinecke, U.
    Hefner, G.
    Helmer, R.
    Janssen, G.
    Jaquenoud, E.
    Laux, G.
    Messer, T.
    Moessner, R.
    Mueller, M. J.
    Paulzen, M.
    Pfuhlmann, B.
    Riederer, P.
    Saria, A.
    Schoppek, B.
    Schoretsanitis, G.
    Schwarz, M.
    Gracia, M. Silva
    Stegmann, B.
    Steimer, W.
    Stingl, J. C.
    Uhr, M.
    Ulrich, S.
    Unterecker, S.
    Waschgler, R.
    Zernig, G.
    Zurek, G.
    Baumann, P.
    [J]. PHARMACOPSYCHIATRY, 2018, 51 (1-2) : 9 - +
  • [7] Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine
    Kuzin, Maxim
    Schoretsanitis, Georgios
    Haen, Ekkehard
    Stegmann, Benedikt
    Hiemke, Christoph
    Gruender, Gerhard
    Paulzen, Michael
    [J]. CLINICAL PHARMACOKINETICS, 2018, 57 (06) : 729 - 737
  • [8] Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects
    Lantz, RJ
    Gillespie, TA
    Rash, TJ
    Kuo, F
    Skinner, M
    Kuan, HY
    Knadler, MP
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (09) : 1142 - 1150
  • [9] Steady-State Concentrations of Mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and their Enantiomers in Relation to Cytochrome P450 2D6 Genotype, Age and Smoking Behaviour
    Lind, Anna-Britta
    Reis, Margareta
    Bengtsson, Finn
    Jonzier-Perey, Michele
    Golay, Kerry Powell
    Ahlner, Johan
    Baumann, Pierre
    Dahl, Marja-Liisa
    [J]. CLINICAL PHARMACOKINETICS, 2009, 48 (01) : 63 - 70
  • [10] Population Pharmacokinetics of Orally Administered Duloxetine in Patients Implications for Dosing Recommendation
    Lobo, Evelyn D.
    Quinlan, Tonya
    O'Brien, Lisa
    Knadler, Mary Pat
    Heathman, Michael
    [J]. CLINICAL PHARMACOKINETICS, 2009, 48 (03) : 189 - 197